Intravenous cyclophosphamide pulse therapy in interstitial lung disease associated with systemic sclerosis in a retrospective open-label study: influence of the extent of inflammation on pulmonary function

Interstitial lung disease (ILD) is the primary cause of death in patients with systemic sclerosis (SSc). It is thought that chronic inflammation is a key component in SSc-ILD. Treatment, such as cyclophosphamide (CYC), targets this inflammation. We hypothesized that treatment with CYC might be more...

Descripción completa

Detalles Bibliográficos
Autores principales: van den Hombergh, W. M. T., Simons, S. O., Teesselink, E., Knaapen-Hans, H. K. A., van den Hoogen, F. H. J., Fransen, J., Vonk, M. C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154086/
https://www.ncbi.nlm.nih.gov/pubmed/29987427
http://dx.doi.org/10.1007/s10067-018-4171-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6154086/
https://www.ncbi.nlm.nih.gov/pubmed/29987427
http://dx.doi.org/10.1007/s10067-018-4171-6

Ejemplares similares